Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical performance of a novel ultrathin strut, low-dose, sirolimus-eluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention in the daily practice.
Prado GF Jr, Ribeiro EE, Melo PH, Pinton FA, Esteves-Filho A, Takimura CK, Mariani J Jr, Kajita LJ, Marchiori G, Araripe Falcao Bde A, Galon MZ, Soares PR, Zalc S, Lemos PA. Prado GF Jr, et al. Among authors: soares pr. Cardiovasc Diagn Ther. 2015 Dec;5(6):414-9. doi: 10.3978/j.issn.2223-3652.2015.07.07. Cardiovasc Diagn Ther. 2015. PMID: 26675281 Free PMC article.
Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II).
Soares PR, Hueb WA, Lemos PA, Lopes N, Martinez EE, Cesar LA, Oliveira SA, Ramires JA. Soares PR, et al. Circulation. 2006 Jul 4;114(1 Suppl):I420-4. doi: 10.1161/CIRCULATIONAHA.105.000679. Circulation. 2006. PMID: 16820611 Clinical Trial.
Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JA. Hueb W, et al. Among authors: soares pr. Circulation. 2010 Sep 7;122(10):949-57. doi: 10.1161/CIRCULATIONAHA.109.911669. Epub 2010 Aug 23. Circulation. 2010. PMID: 20733102 Clinical Trial.
Hypotheses, rationale, design, and methods for prognostic evaluation in type 2 diabetic patients with angiographically normal coronary arteries. The MASS IV-DM Trial.
Hueb W, Lopes N, Soares PR, Gersh BJ, Lima EG, Vieira RD, Garzillo CL, Garcia RR, Pereira AC, Strunz CM, Meneguetti C, Tsutsui J, Parga J, Lemos P, Hueb A, Ushida A, Maranhão R, Chamone DA, Ramires JA. Hueb W, et al. Among authors: soares pr. BMC Cardiovasc Disord. 2010 Sep 29;10:47. doi: 10.1186/1471-2261-10-47. BMC Cardiovasc Disord. 2010. PMID: 20920271 Free PMC article. Clinical Trial.
Hypotheses, rationale, design, and methods for prognostic evaluation of cardiac biomarker elevation after percutaneous and surgical revascularization in the absence of manifest myocardial infarction. A comparative analysis of biomarkers and cardiac magnetic resonance. The MASS-V Trial.
Hueb W, Gersh BJ, Rezende PC, Garzillo CL, Lima EG, Vieira RD, Garcia RM, Favarato D, Segre CA, Pereira AC, Soares PR, Ribeiro E, Lemos P, Perin MA, Strunz CC, Dallan LA, Jatene FB, Stolf NA, Hueb AC, Dias R, Gaiotto FA, da Costa LM, Oikawa FT, de Melo RM, Serrano CV Jr, de Ávila LF, Villa AV, Filho JR, Nomura C, Ramires JA, Kalil Filho R; MASS-V Study Group. Hueb W, et al. Among authors: soares pr. BMC Cardiovasc Disord. 2012 Aug 16;12:65. doi: 10.1186/1471-2261-12-65. BMC Cardiovasc Disord. 2012. PMID: 22898311 Free PMC article. Clinical Trial.
A Novel Algorithm to Quantify Coronary Remodeling Using Inferred Normal Dimensions.
Falcão BA, Falcão JL, Morais GR, Silva RC, Lopes AC, Soares PR, Mariani J Jr, Kalil-Filho R, Edelman ER, Lemos PA. Falcão BA, et al. Among authors: soares pr. Arq Bras Cardiol. 2015 Oct;105(4):390-8. doi: 10.5935/abc.20150098. Epub 2015 Aug 18. Arq Bras Cardiol. 2015. PMID: 26559986 Free PMC article.
Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).
Lemos PA, Serruys PW, de Feyter P, Mercado NF, Goedhart D, Saia F, Arampatzis CA, Soares PR, Ciccone M, Arquati M, Cortellaro M, Rutsch W, Legrand V. Lemos PA, et al. Among authors: soares pr. Am J Cardiol. 2005 Feb 15;95(4):445-51. doi: 10.1016/j.amjcard.2004.10.008. Am J Cardiol. 2005. PMID: 15695126 Free article. Clinical Trial.
86 results